Siyuan Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Siyuan Dai has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Ahmet R. Ozturk
RNA Therapeutic Institute, UMass Chan Medical School, Worcester, MA 01605, USA
1 shared publicationAltair L. Dube
RNA Therapeutic Institute, UMass Chan Medical School, Worcester, MA 01605, USA
1 shared publication- Craig C. Mello
RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA; Howard Hughes Medical Institute, Worcester, MA 01605, USA
1 shared publication - En-Zhi Shen
Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China
1 shared publication Hao Chen
Program in Bioinformatics and Integrative Biology, UMass Chan Medical School, Worcester, MA 01605, USA
1 shared publication- Jian-Ping Ning
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
1 shared publication
Latest Publications
- Open Access
- 6 September 2022
- Published by Elsevier in Cell Reports
- Vol. 40 (10) , 111265
A family of C. elegans VASA homologs control Argonaute pathway specificity and promote transgenerational silencing
- 6 September 2022
- Published by Elsevier in Cell Reports
- Vol. 40 (10) , 111265
Open AccessA family of C. elegans VASA homologs control Argonaute pathway specificity and promote transgenerational silencing
- 4 April 2019
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 30 (8) , 608-628
Immobilizing argatroban and mPEG-NH2 on a polyethersulfone membrane surface to prepare an effective nonthrombogenic biointerface
Systemic anticoagulation is not suitable for hemodialysis (HD) patients with a high risk of bleeding in the clinic. An HD membrane that provides a localized anticoagulation membrane surface may be a promising strategy to solve this intractable problem for HD patients. Herein, we modified a nonthrombogenic polyethersulfone (PES) dialyzer membrane by grafting argatroban (AG) and methoxy polyethylene glycol amine (mPEG-NH2) via a polydopamine (PDA) strategy. The PES substrates were immersed in an alkaline dopamine solution for 24 h, and then, AG and mPEG-NH2 were sequentially grafted covalently onto the resultant membrane. Attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR) and X-ray photoelectron spectroscopy (XPS) were utilized to confirm the successful introduction of PDA and the immobilization of AG and mPEG-NH2. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) were used to observe the surface structure and morphology after the surface modification. The excellent antithrombotic abilities of the modified membrane were demonstrated by the suppression of platelet adhesion and activation, prolongation of clotting times, and inhibition of thrombin generation and complement activation. This work describes an efficient and convenient method to immobilize AG and mPEG-NH2 to create a nonthrombogenic biointerface for blood-contacting devices such as HD membranes.
- 4 April 2019
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 30 (8) , 608-628
Immobilizing argatroban and mPEG-NH2 on a polyethersulfone membrane surface to prepare an effective nonthrombogenic biointerface
Systemic anticoagulation is not suitable for hemodialysis (HD) patients with a high risk of bleeding in the clinic. An HD membrane that provides a localized anticoagulation membrane surface may be a promising strategy to solve this intractable problem for HD patients. Herein, we modified a nonthrombogenic polyethersulfone (PES) dialyzer membrane by grafting argatroban (AG) and methoxy polyethylene glycol amine (mPEG-NH2) via a polydopamine (PDA) strategy. The PES substrates were immersed in an alkaline dopamine solution for 24 h, and then, AG and mPEG-NH2 were sequentially grafted covalently onto the resultant membrane. Attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR) and X-ray photoelectron spectroscopy (XPS) were utilized to confirm the successful introduction of PDA and the immobilization of AG and mPEG-NH2. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) were used to observe the surface structure and morphology after the surface modification. The excellent antithrombotic abilities of the modified membrane were demonstrated by the suppression of platelet adhesion and activation, prolongation of clotting times, and inhibition of thrombin generation and complement activation. This work describes an efficient and convenient method to immobilize AG and mPEG-NH2 to create a nonthrombogenic biointerface for blood-contacting devices such as HD membranes.